Guidelines for the Management of Patients with Alopecia Areata in Korea: Part II Systemic Treatment

Abstract

Background Alopecia areata (AA) is a chronic disease with an unpredictable course and can have a severe psychological impact on an individual. Objective To provide evidence and consensus-based statements regarding the treatment of patients with AA in Korea. Methods We searched for relevant studies from inception to May 2021 regarding the systemic treatment of AA. Evidence-based recommendations were also prepared. The evidence for each statement was graded and classified according to the strength of the recommendations. Hair experts from the Korean Hair Research Society (KHRS) voted on the statement, and an agreement of 75% or greater was considered as having reached consensus. Results Current evidence supports the efficacy of systemic corticosteroids, oral cyclosporine monotherapy or combination with systemic corticosteroids, and oral Janus kinase inhibitors in severe AA patients. Systemic steroids may be considered for pediatric patients with severe AA. A consensus was achieved in three out of nine (33.3%), and one out of three (33.3%) statements pertaining to systemic treatment in adult and pediatric AA, respectively. Conclusion The present study produced up-to-date, evidence-based treatment guidelines for AA associated with the consensus obtained by experts based on the Korean healthcare system.

The new era of JAK inhibitors: Impelling updates in Alopecia Areata Guideline

“…Ultimately, eight articles were selected. [1][2][3][4][5][6][7][8] The principal objective of this study was to ascertain the incorporation and extent of JAK inhibitors in the most recent guidelines by different regions and associations. We compared the recommendations, treatment algorithms and descriptions of the JAK inhibitors (Table 1).…”

“…Our findings revealed that mentions of JAK inhibitors in official guidelines began to emerge in 2019. While guidelines published in Australia, Italy and Russia only made passing references to JAK inhibitors, 1,4,5 those published in the USA, Brazil and Korea went a step further, proposing JAK inhibitors as a first-line 7,8 or second-line 6 treatment modality (Figure 1, Table 1).…”